Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: senior level changes at Lilly; mRNA COVID vaccines and booster shots; GSK and Sanofi deal with a changed vaccines landscape; a look ahead at new drugs for hematological malignancies; and a huge fundraising in China for an mRNA specialist.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 20 August 2021, including: senior level changes at Eli Lilly and Company; mRNA COVID vaccines and booster shots; GlaxoSmithKline plc and Sanofi deal with a changed vaccines landscape; a look ahead at new drugs for hematological malignancies; and a huge fundraising in China for an mRNA specialist.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Musical Chairs: Lilly Leadership Changes Underscore Confidence In Donanemab Accelerated Approval" - Scrip, 17 Aug, 2021.)
(Also see "Pfizer/BioNTech, Moderna Vaccines Take Baby Steps Into Booster Shots" - Scrip, 13 Aug, 2021.)
(Also see "Can Sanofi And GSK Catch Up In mRNA Vaccines?" - Scrip, 17 Aug, 2021.)
(Also see "12 Key Oncology Drug Launches Expected In 2022 – Hematological Malignancies" - Scrip, 19 Aug, 2021.)
(Also see "'Moderna Of China' Gets $700m Injection As Investors Bet Big On Domestic mRNA Vaccines" - Scrip, 20 Aug, 2021.)